The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation

Pediatric Transplantation

Volumn 14, Issue 6, 2010, Pages 753-760

  Lapidus Krol, E ^a   Shapiro, R ^a   Amir, J ^a   Davidovits, M ^a   Steinberg, R ^a   Mor, E ^a   Avitzur, Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

antiviral prophylaxis; children; cytomegalovirus infectionsdisease; ganciclovirvalganciclovir; kidneyliver transplantation; risk factors

Indexed keywords

CORTICOSTEROID; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ALLOGRAFT; ARTICLE; CADAVER DONOR; CADAVER KIDNEY; CHILD; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRITIS; GRAFT RECIPIENT; HEPATITIS; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRESCHOOL CHILD; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 77955815629     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2010.01330.x     Document Type: Article

References (33)

1. Keough WL, Michaels MG. Infectious complications in pediatric solid organ transplantation. Pediatr Clin North Am 2003 : 50 : 1451 1469.
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998 : 338 : 1741 1751.
3. Falagas ME, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997 : 63 : 1595 1601.
4. Evans PC, Soin A, Wreghitt TG, et al. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000 : 69 : 30 35.
5. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996 : 22 : 537 549.
6. Bueno J, Ramil C, Green M. Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 2002 : 4 : 279 290.
7. Hodson EM, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005 : 4 : CD003774.
8. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005 : 65 : 859 878.
9. Pescovitz MD, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 : 44 : 2811 2815.
10. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000 : 13 : 83 121, table of contents.
11. Gane E, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997 : 350 : 1729 1733.
12. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999 : 39 : 800 804.
13. Paya C, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 : 4 : 611 620.
14. Vaudry W, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009 : 9 : 636 643.
15. Clark BS, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004 : 77 : 1480.
16. Pescovitz MD, Brook B, Jindal RM, et al. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study. Clin Transplant 1997 : 11 : 613 617.
17. Anaizi NH, Dentinger PJ, Swenson CF. Stability of valganciclovir in an extemporaneously compounded oral liquid. Am J Health Syst Pharm 2002 : 59 : 1267 1270.
18. Pescovitz MD, Jain A, Robson R, et al. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. Transplant Proc 2007 : 39 : 3111 3116.
19. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 : 34 : 1094 1097.
20. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005 : 5 : 218 227.
21. Bock GH, et al. Cytomegalovirus infections following renal transplantation - effects on antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997 : 11 : 665 671.
22. Iragorri S, Pillay D, Scrine M, et al. Prospective cytomegalovirus surveillance in paediatric renal transplant patients. Pediatr Nephrol 1993 : 7 : 55 60.
23. Mellon A, et al. Cytomegalovirus infection after liver transplantation in children. J Gastroenterol Hepatol 1993 : 8 : 540 544.
24. Robinson LG, et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002 : 6 : 111 118.
25. Akalin E, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003 : 3 : 731 735.
26. Keven K, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004 : 36 : 3107 3112.
27. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006 : 12 : 112 116.
28. Jain A, et al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients. Transplant Proc 2005 : 37 : 3182 3186.
29. Paya CV, Razonable RR. Cytomegalovirus infection after solid organ transplantation. In : Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections.
30. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005 : 8 (Suppl 1 S7 S13.
31. Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993 : 5 (Suppl 4 15 21.
32. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 : 23 : 1296 1310.
33. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984 : 6 : 592 599.